Literature DB >> 28087785

Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Brian F Thomas1, Timothy W Lefever2, Ricardo A Cortes2, Megan Grabenauer2, Alexander L Kovach2, Anderson O Cox2, Purvi R Patel2, Gerald T Pollard2, Julie A Marusich2, Richard C Kevin2, Thomas F Gamage2, Jenny L Wiley1.   

Abstract

Synthetic cannabinoids are manufactured clandestinely with little quality control and are distributed as herbal "spice" for smoking or as bulk compound for mixing with a solvent and inhalation via electronic vaporizers. Intoxication with synthetic cannabinoids has been associated with seizure, excited delirium, coma, kidney damage, and other disorders. The chemical alterations produced by heating these structurally novel compounds for consumption are largely unknown. Here, we show that heating synthetic cannabinoids containing tetramethylcyclopropyl-ring substituents produced thermal degradants with pharmacological activity that varied considerably from their parent compounds. Moreover, these degradants were formed under conditions simulating smoking. Some products of combustion retained high affinity at the cannabinoid 1 (CB1) and CB2 receptors, were more efficacious than (-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol (CP55,940) in stimulating CB1 receptor-mediated guanosine 5'-O-(3-thiotriphosphate) (GTPγS) binding, and were potent in producing Δ9-tetrahydrocannabinol-like effects in laboratory animals, whereas other compounds had low affinity and efficacy and were devoid of cannabimimetic activity. Degradants that retained affinity and efficacy also substituted in drug discrimination tests for the prototypical synthetic cannabinoid 1-pentyl-3-(1-naphthoyl)indole (JWH-018), and are likely to produce psychotropic effects in humans. Hence, it is important to take into consideration the actual chemical exposures that occur during use of synthetic cannabinoid formulations to better comprehend the relationships between dose and effect.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28087785      PMCID: PMC5363769          DOI: 10.1124/jpet.116.238717

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  41 in total

1.  Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.

Authors:  G Griffin; P J Atkinson; V M Showalter; B R Martin; M E Abood
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

2.  An outbreak of exposure to a novel synthetic cannabinoid.

Authors:  Andrew A Monte; Alvin C Bronstein; Dazhe J Cao; Kennon J Heard; Jason A Hoppe; Christopher O Hoyte; Janetta L Iwanicki; Eric J Lavonas
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

3.  Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Behav Pharmacol       Date:  2015-08       Impact factor: 2.293

4.  Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use.

Authors:  R Tse; S Kodur; B Squires; N Collins
Journal:  Intern Med J       Date:  2014-09       Impact factor: 2.048

5.  Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order.

Authors: 
Journal:  Fed Regist       Date:  2014-02-10

6.  Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22.

Authors:  George Behonick; Kevin G Shanks; Dennis J Firchau; Gagan Mathur; Charles F Lynch; Marcus Nashelsky; David J Jaskierny; Chady Meroueh
Journal:  J Anal Toxicol       Date:  2014-05-29       Impact factor: 3.367

7.  Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Megan Grabenauer; Katherine N Moore; John W Huffman; Brian F Thomas
Journal:  Neuropharmacology       Date:  2016-07-20       Impact factor: 5.250

8.  Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay.

Authors:  Annelies Cannaert; Jolien Storme; Florian Franz; Volker Auwärter; Christophe P Stove
Journal:  Anal Chem       Date:  2016-11-07       Impact factor: 6.986

9.  Suicidal ideation and self-harm following K2 use.

Authors:  Shannon Thomas; Sarah Bliss; Mohammed Malik
Journal:  J Okla State Med Assoc       Date:  2012-11

10.  Notes from the Field: Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use - United States, January-May 2015.

Authors:  Royal Law; Josh Schier; Colleen Martin; Arthur Chang; Amy Wolkin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-12       Impact factor: 17.586

View more
  13 in total

1.  In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors.

Authors:  Shivani Sachdev; Kiran Vemuri; Samuel D Banister; Mitchell Longworth; Michael Kassiou; Marina Santiago; Alexandros Makriyannis; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-12-10       Impact factor: 8.739

2.  The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Brian F Thomas; Thuy Nguyen; Yanan Zhang; Jenny L Wiley
Journal:  Neuropharmacology       Date:  2017-08-10       Impact factor: 5.250

3.  Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Ryan J McKinnie; Richard C Kevin; Iain S McGregor; Mark L Trudell; Jenny L Wiley; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2018-12-14       Impact factor: 4.030

4.  Comparison of the discriminative stimulus and response rate effects of Δ9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2017-01-11       Impact factor: 4.492

5.  Highly sensitive screening and analytical characterization of synthetic cannabinoids in nine different herbal mixtures.

Authors:  Vera L Alves; João L Gonçalves; Joselin Aguiar; Maria J Caldeira; Helena M Teixeira; José S Câmara
Journal:  Anal Bioanal Chem       Date:  2021-02-11       Impact factor: 4.142

6.  Do you feel it now? Route of administration and Δ9-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice.

Authors:  Jenny L Wiley; Timothy W Lefever; Michelle Glass; Brian F Thomas
Journal:  Neurotoxicology       Date:  2019-04-03       Impact factor: 4.294

7.  Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Julie A Marusich; Richard C Kevin; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2018-03-16       Impact factor: 4.030

8.  In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.

Authors:  Thomas F Gamage; Daniel G Barrus; Richard C Kevin; David B Finlay; Timothy W Lefever; Purvi R Patel; Megan A Grabenauer; Michelle Glass; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  Pharmacol Biochem Behav       Date:  2020-04-02       Impact factor: 3.533

9.  Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures.

Authors:  Richard C Kevin; Alexander L Kovach; Timothy W Lefever; Thomas F Gamage; Jenny L Wiley; Iain S McGregor; Brian F Thomas
Journal:  Forensic Toxicol       Date:  2018-06-28       Impact factor: 4.096

10.  Δ9-Tetrahydrocannabinol discrimination: Effects of route of administration in rats.

Authors:  Jenny L Wiley; Shanequa I Taylor; Julie A Marusich
Journal:  Drug Alcohol Depend       Date:  2021-06-23       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.